Medtronic reached a critical juncture last month in its quest to build the market for renal denervation, a new device-based ...
Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.
CEO Ivan Tornos said multiple factors emerged late in the quarter that caused the shortfall. Zimmer’s shares plunged more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback